

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



The
Patent
Office

09/508892
PCT/EP 98/05720

REC'D 18 NOV 1998
WIPO
PCT

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP9 1RH

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)


I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely substitutes the company to certain additional company law rules.

Signed *Andrew Gersey*
Dated 15 June 1998





For official use

12 MAY 1998

THE PATENT OFFICE

12 MAY 1998

RECEIVED BY HAND

9

13MAY98 E360040-1 D01298

P01/7700 25.00 - 9810143.9

Your reference

PCS9455JRH-PROV2

9810143.9

Notes

Please type, or write in dark ink using CAPITAL letters. A prescribed fee is payable for a request for grant of a patent. For details, please contact the Patent Office (telephone 071-438 4700).

Rule 16 of the Patents Rules 1990 is the main rule governing the completion and filing of this form.

2 Do not give trading styles, for example, 'Trading as XYZ company', nationality or former names, for example, 'formerly (known as) ABC Ltd' as these are not required.

Warning

Where an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977 and will inform the applicant if such prohibition or restriction is necessary. Applicants resident in the United Kingdom are also reminded that under Section 23, applications may not be filed abroad without written permission unless an application has been filed not less than 6 weeks previously in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction revoked.

The
Patent
Office

Request for grant of a Patent Form 1/77

Patents Act 1977

1 Title of invention

PARASITICIDAL FORMULATIONS

1 Please give the title of the invention

2 Applicant's details

☐ First or only applicant

2a If you are applying as a corporate body please give:

Corporate name
PFIZER LIMITED

Country (and State of incorporation, if appropriate)
UNITED KINGDOM

2b If you are applying as an individual or one of a partnership please give in full:

Surname
Forenames

2c In all cases, please give the following details:

Address
RAMSGATE ROAD,
SANDWICH, KENT,

UK postcode CT13 9NJ
(if applicable)

Country UNITED KINGDOM

ADP number
(if known)

6872673001

2d, 2e and 2f:

If there are further applicants
please provide details on a separate
sheet of paper.

☐ Second applicant (if any)

2d If you are applying as a corporate body please give:

Corporate name

Country (and State of incorporation, if appropriate)

2e If you are applying as an individual or one of a partnership please give in full:

Surname

Forenames

2f In all cases, please give the following details:

Address

UK postcode
(if applicable)

Country

ADP number
(if known)

3

An address for service in the United
Kingdom must be supplied.

Please mark correct box

3 Address for service details

3a Have you appointed an agent to deal with your application?

Yes ☒ No ☐ ➔ go to 3b



Please give details below

Agent's name

MR J.R. HAYLES

Agent's address

PFIZER LIMITED

RAMSGATE ROAD

SANDWICH

KENT

Postcode CT13 9NJ

Agent's ADP
number

6409893002

3b:

If you have appointed an agent,
all correspondence concerning
your application will be sent to
the agent's United Kingdom
address.

3b If you have not appointed an agent please give a name and address in the United
Kingdom to which all correspondence will be sent:

Name

Address

Postcode
ADP number
(if known)

Daytime telephone
number (if available)

PCS9455JRH-PROV2

5 Claiming an earlier application date

5 Are you claiming that this application be treated as having been filed on the date of filing of an earlier application?

Please mark correct box

Yes ☐ No ☒ **➡ go to 6**



please give details below

☐ number of earlier application or patent number

 filing date

(day month year)

☐ and the Section of the Patents Act 1977 under which you are claiming:

Please mark correct box

15(4) (Divisional) ☐ 8(3) ☐ 12(6) ☐ 37(4) ☐

6

If you are declaring priority from a PCT Application please enter 'PCT' as the country and enter the country code (for example, GB) as part of the application number.

Please give the date in all number format, for example, 31/05/90 for 31 May 1990.

6 Declaration of priority

6 If you are declaring priority from previous application(s), please give:

Country of filing

Priority application number
(if known)

Filing date
(day,month,year)

7

The answer must be 'No' if:
 - any applicant is not an inventor
 - there is an inventor who is not an applicant, or
 - any applicant is a corporate body.

8

Please supply duplicates of claim(s), abstract, description and drawing(s).

Please mark correct box(es)

9

You or your appointed agent (see Rule 90 of the Patents Rules 1990) must sign this request.

Please sign here →

A completed fee sheet should preferably accompany the fee.

7 Inventorship

7 Are you (the applicant or applicants) the sole inventor or the joint inventors?

Please mark the correct box

Yes ☐ No ☒ →

A statement of Inventorship on Patents Form 7/77 will need to be filed (see Rule 15).

8 Checklist

8a Please fill in the number of sheets for each of the following types of document contained in this application.

Continuation sheets for this Patents Form 1/77

Claim(s)

2

Description

8

Abstract

Drawing(s)

2

8b Which of the following documents also accompanies the application?

Priority documents (please state how many)

Translation(s) of Priority documents (please state how many)

Patents Form 7/77 - Statement of Inventorship and Right to Grant (please state how many)

Patents Form 9/77 - Preliminary Examination/Search

Patents Form 10/77 - Request for Substantive Examination

9 Request

I/We request the grant of a patent on the basis of this application.

Signed

J.R. HAYLES
 J.R. HAYLES

Date 12/05/1998

(day month year)

Please return the completed form, attachments and duplicates where requested, together with the prescribed fee to:

☐ The Comptroller
 The Patent Office
 Cardiff Road
 NEWPORT
 Gwent
 NP9 1RH

The Comptroller
 The Patent Office
 25 Southampton Buildings
 London
 WC2A 1AY


Parasiticial formulations

This invention relates to a solid implant containing a parasiticial compound having low aqueous solubility, which is particularly useful for administration to livestock such as cattle, pigs and sheep.

A number of potent macrocyclic parasiticial compounds are known, including the avermectins and milbemycins. UK Patent N° 1,573,955 discloses a family of avermectin compounds (including avermectins B1a and B1b) which are indicated as parasiticides.

22,23-Dihydroavermectin B1 (ivermectin, disclosed in EP 1689) is available commercially in an injectable formulation (sold as IVOMECTTM). Ivermectin is a mixture of at least 80% 22,23-dihydroavermectin B1a (having a 25-sec butyl group) and not more than 20% of 22,23-dihydroavermectin B1b (having a 25-isopropyl group).

25-Cyclohexyl-avermectin B1 (doramectin, disclosed in EP 214731) has the following structure,



and is available commercially in an oil formulation for injection (sold as DECTOMAXTM) for the treatment and prevention of internal and external parasite infestations in cattle. The oil formulation is described in European Patent N° 393890.

The milbemycins are similar in structure to the avermectins, except that they are unsubstituted at the 13-position.

Although formulations such as DECTOMAX™ have been successful, there is a need for
5 further formulations which are convenient to administer and which provide prolonged protection against parasites.

Thus, according to the present invention, there is provided a solid implant comprising at least one parasitocidal compound having low aqueous solubility; and tableting excipients
10 including a bulking agent.

Implants according to the invention may be implanted intramuscularly. Preferably however, they are implanted subcutaneously (i.e. into the fatty tissue directly below the skin).

15

Suitable parasitocidal compounds are those having an aqueous solubility below 100 µg/ml, for example the avermectins and milbemycins. Doramectin is of particular interest (which has an aqueous solubility of 0.6 µg/ml at pH 7). Ivermectin is also of interest.

20 Preferably, the bulking agent is lactose. Other suitable bulking agents include other sugars, microcrystalline cellulose (which is available commercially as AVICEL™) and dicalcium phosphate.

Other tableting excipients which may be present include magnesium stearate, which acts
25 as a lubricant to facilitate tableting. Typically, magnesium stearate will make up about 3% of the implant, by weight. Binding agents may also be included in the formulation to aid granulation and compressibility. Examples of binding agents include starch, gelatin and polyvinyl pyrrolidone. Typically, the binding agent, when present, will make up between 2 to 10% of the implant, by weight.

30

A further tableting excipient which the implants of the invention may optionally contain is a tablet disintegrant. Suitable tablet disintegrants include sodium starch glycolate, which

is available commercially as EXPLOTAB™. Other disintegrants which may be mentioned are dicalcium phosphate and cross-linked starch. Typically, the disintegrant, when present, will make up about 5% of the implant, by weight.

- 5 Preferably, the parasiticial compound (or compounds) makes up between 10 and 60% of the implant, by weight, more preferably from 20 to 45% of the implant, by weight, for example 40%.

10 Preferably, the implants of the invention contain an antioxidant or a reducing agent. It has been found that such additives reduce or eliminate degradation of the parasiticial compound, thus extending the shelf-life of the implant. It has been found that such additives are particularly useful for stabilizing the parasiticial compound when the implant is sterilized by irradiation, such as gamma or beta irradiation.

- 15 Antioxidants of particular interest are butylated hydroxy anisole (BHA; a mixture of 2-*tert*-butyl-4-methoxyphenol and 3-*tert*-butyl-4-methoxyphenol) and butylated hydroxy toluene (BHT; 2,6-di-*tert*-butyl-4-methylphenol). Other antioxidants and reducing agents include alpha-tocopherol, alkyl gallate derivatives, nordihydroguaiaretic acid, ascorbic acid, sodium metabisulphate and sodium sulphite. Typically, the antioxidant, when present, will
20 make up between 0.01 to 0.5% of the implant, by weight, more preferably 0.1 to 0.2%.

As mentioned above, the implants of the invention may be irradiated to sterilize them, typically at a dose in the range 15-25 kGy (kilo Gray).

- 25 The implants of the invention may be implanted in various parts of the animal to be treated, for example the flank, the base of the tail or the ear. Where the ears are removed during a meat rendering process, this is a preferred site for implantation.

To facilitate such implantation, the implants are preferably rod-shaped, and can be
30 implanted conveniently using a conventional hand-operated implant gun. Suitably, rod-shaped implants are 2 to 30 mm in length, and 2 to 5 mm in diameter. Preferred

dimensions are 5 to 6 mm in length, and 2 to 3 mm in diameter. Preferably, the cross section is circular.

According to the invention, there is also provided a method for the treatment or prevention
5 of parasitic infections which comprises administering an implant as defined above to an animal in need of such treatment.

Parasitic infections of particular interest are those caused by endoparasites including helminthiasis (most frequently caused by nematode worms in the gastrointestinal tract).
10 The implants are also useful in treatment or prevention of ectoparasite infections such as of ticks, mites, lice, fleas, blowfly, biting insects and migrating dipterous larvae.

The dosage to be administered will depend on the animal to be treated, the parasitocidal compound being used, and the condition to be treated. However, a suitable dose of
15 doramectin is 0.5 mg/kg of animal body weight. Typically, an implant according to the invention having the preferred dimensions mentioned above will contain about 10 mg of doramectin. Thus, for cattle weighing 120 kg, 6 implants will be needed. This provides sustained release of doramectin for up to 26 weeks. Where multiple implants are required, these can often be implanted consecutively by a single actuation of an implant gun.

20

The implants of the invention may be prepared by dry- or wet-mass granulation followed by milling and compression into the desired shape using conventional techniques.

The duration of action of the implants of the invention may be determined by measuring
25 blood plasma levels in cattle following implantation. These levels have been correlated with antiparasitic activity of the compounds which have established that for effective control of helminths a blood plasma level of about 2 ng/ml needs to be maintained, and that for effective control of single-host ticks a blood plasma level of about 5 ng/ml needs to be maintained.

30

In a broader aspect, the invention further provides use of an antioxidant or a reducing agent in a composition containing an avermectin or a milbemycin for preventing degradation of

the avermectin or milbemycin. Although BHA has been used previously in association with doramectin in DECTOMAX™, its function was to prevent rancidity of the oil formulation rather than to aid the stability of doramectin in solution. This aspect of the invention is particularly useful when the formulation is irradiated, and may be used in liquid and non-liquid formulations (such as solids and powders).

The invention is illustrated by the following examples, and the accompanying Figures in which:

Figure 1 shows the blood plasma levels in cattle achieved by the implants prepared in Examples 1 and 2; and

Figure 2 shows the degradation profiles of implants prepared in Example 4.

Example 1

Doramectin implant

Components	Specification	mg/unit	% by weight
Doramectin ^a	Pfizer	10.000	40
β-anhydrous lactose	Ph Eur	14.250	57
Magnesium stearate	Ph Eur	0.750	3
Total		25.000	100

^a mean particle size 19.27 μm (volume mean diameter)

The components, except magnesium stearate, were blended together in a blender for 15 minutes. The blend was then sieved through a 680 μm mesh screen and blended for a further 15 minutes. After that, half of the magnesium stearate was added and blending continued for 5 minutes, after which the blend was compressed to form "slugs". The slugs were then milled to form granules, and the size fraction 250-355 μm was collected.

The collected granules were then blended for 15 minutes, and then the remaining half of the magnesium stearate was added and blending continued for 5 minutes. The blend was

then compressed on a suitable tablet machine using 2 mm tooling to produce rod-shaped implants of 2 mm diameter and 5 mm length.

Example 2

5 Doramectin implant containing a tablet disintegrant

Components	Specification	mg/unit	% by weight
Doramectin ^a	Pfizer	10.000	40
β-anhydrous lactose	Ph Eur	13.000	52
Sodium starch glycolate (EXPLATAB™)	BP	1.250	5
Magnesium stearate	Ph Eur	0.750	3
Total		25.000	100

^a mean particle size 19.27 µm (volume mean diameter)

- 10 The implants were prepared by the method of Example 1.

Example 3

Pharmacokinetic profiling

- 15 The implants of Examples 1 and 2 were implanted into 16 cows at a dose of 500µg/kg. The blood plasma concentrations of doramectin following implantation were measured, and the results are shown in Figure 1. It can be seen that in each case single-host tick activity was obtained for more than 50 days, and control of helminths was obtained for about 90 days.

20

Example 4

Doramectin implant containing an antioxidant

Components	Specification	mg/unit	% by weight
------------	---------------	---------	-------------

Doramectin ^a	Pfizer	10.000	40
β -anhydrous lactose	Ph Eur	11.625	46.5
Sodium starch glycolate (EXPLOTAB TM)	BP	1.250	5
Butylated hydroxy anisole	Ph Eur	0.125	0.5
Polyvinyl pyrrolidone	Ph Eur	1.250	5
Magnesium stearate	Ph Eur	0.750	3
Total		25.000	100

The components, except magnesium stearate, butylated hydroxy anisole and polyvinyl pyrrolidone, were blended together in a blender for 15 minutes. The blend was then sieved through a 680 μ m mesh screen and blended for a further 15 minutes. After that, the butylated hydroxy anisole and polyvinyl pyrrolidone was dissolved in ethanol to form the granulation fluid. The volume of ethanol used was approximately 20%, by volume, of the total formulation. The granulation fluid was sprayed onto the blend under constant mixing over 10 minutes. The resultant wet granule mass was sieved through a 1.4 mm mesh screen and allowed to dry under vacuum for 3 hours at 50°C. The dried granules were then milled, and the size fraction 250-355 μ m was collected.

The collected granules were then blended for 15 minutes, and the magnesium stearate was added and blending continued for a further 5 minutes. The blend was then compressed on a suitable tableting machine using a 2mm tooling to produce rod-shaped implants of 2mm diameter and 5 mm length.

These implants were used in stability studies, in which the effects of BHA and electron beam irradiation were investigated. Implants containing 0.5% w/w BHA and having been treated at four different irradiation levels [control (0 kGy), 15 kGy, 20 kGy and 25 kGy] were stored at 30°C for 30 weeks, and then the percentage of doramectin remaining was determined. A control implant containing no BHA was also studied.

The results are shown in Figure 2. It can be seen that the presence of BHA dramatically improves the stability of the implants on storage, even when the implants have been irradiated.

Claims:

1. A solid implant comprising at least one parasitocidal compound having low aqueous solubility; and tableting excipients including a bulking agent.
- 5 2. An implant as claimed in claim 1, which is adapted for subcutaneous implantation.
3. An implant as claimed in claim 1 or claim 2, wherein the parasitocidal compound has an aqueous solubility below 100 µg/ml.
4. An implant as claimed in claim 3, wherein the parasitocidal compound is an avermectin or a milbemycin.
- 10 5. An implant as claimed in claim 4, wherein the parasitocidal compound is doramectin.
6. An implant as claimed in any one of the preceding claims, wherein the bulking agent is lactose.
7. An implant as claimed in any one of the preceding claims, wherein the tableting excipients include magnesium stearate.
- 15 8. An implant as claimed in any one of the preceding claims, wherein the tableting excipients include a tablet disintegrant.
9. An implant as claimed in claim 8, wherein the tablet disintegrant is sodium starch glycolate.
- 20 10. An implant as claimed in any one of the preceding claims, which contains an antioxidant or a reducing agent.
11. An implant as claimed in claim 10, wherein the antioxidant is butylated hydroxy toluene or butylated hydroxy anisole.
12. An implant as claimed in any one of the preceding claims, which is sterilized by irradiation.
- 25 13. An implant as claimed in any one of the preceding claims, wherein the tableting excipients include polyvinyl pyrrolidone.
14. An implant as claimed in any one of the preceding claims, wherein the parasitocidal compound makes up between 10 and 60% of the implant, by weight.
- 30 15. An implant as claimed in any one of the preceding claims, which is adapted for implantation into the ears of cattle or sheep.
16. An implant as claimed in any one of the preceding claims, which is rod-shaped.

17. A method for the treatment or prevention of parasitic infections which comprises administering an implant as defined in any one of claims 1-16 to an animal in need of such treatment.
18. Use of an antioxidant or a reducing agent in a formulation containing an avermectin
5 or a milbemycin for preventing degradation of the avermectin or milbemycin.
19. The use as claimed in claim 18, wherein the formulation is irradiated.
20. The use as claimed in claim 18 or claim 19, wherein the formulation is not liquid.




Figure 1






Figure 2

